Nearly 30 representatives yesterday urged House leaders to modify in the next COVID-19 response package impending thresholds for qualifying participants in Advanced Alternative Payment Models, which they said threaten to “derail” the movement to value-based care under the Medicare Access and CHIP Reauthorization Act.

“It has become clear that COVID-19 will make it more challenging for many of these providers to meet the law’s current thresholds due to shifts in care,” the House members wrote. “According to data recently released by the Centers for Medicare & Medicaid Services, on average, providers missed even the current QP threshold (50%) and are nowhere near the heightened threshold (75%) required by statute in 2021. It is critical for seniors that APMs continue in 2021 and beyond. Providers participating in APMs are conducting care coordination strategies that are needed now more than ever.”

Reps. Suzan DelBene, D-Wash., Roger Marshall, R-Kan., Peter Welch, D-Vt., and Darin LaHood, R-Ill., spearheaded the letter with support from AHA and other national hospital and physician organizations.

Related News Articles

Headline
The 1st U.S. Circuit Court of Appeals Jan. 7 denied the government’s motion for a stay in a lawsuit filed by the AHA, the Maine Hospital Association and four…
Headline
The Food and Drug Administration today released two guidance documents; one related to low-risk wellness products (including certain wearable devices) and the…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services announced Dec. 18 that it will launch a voluntary payment model designed to broadly reach more…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Blog
Public
Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4…